These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 27386755)

  • 21. Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice.
    Chung S; Ma X; Liu Y; Lee D; Tittiger M; Ponder KP
    Mol Genet Metab; 2007 Feb; 90(2):181-92. PubMed ID: 16979922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.
    Dickson PI; Ellinwood NM; Brown JR; Witt RG; Le SQ; Passage MB; Vera MU; Crawford BE
    Mol Genet Metab; 2012 May; 106(1):68-72. PubMed ID: 22402327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I.
    Hinderer C; Bell P; Gurda BL; Wang Q; Louboutin JP; Zhu Y; Bagel J; O'Donnell P; Sikora T; Ruane T; Wang P; Haskins ME; Wilson JM
    Mol Ther; 2014 Dec; 22(12):2018-2027. PubMed ID: 25027660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I.
    Dierenfeld AD; McEntee MF; Vogler CA; Vite CH; Chen AH; Passage M; Le S; Shah S; Jens JK; Snella EM; Kline KL; Parkes JD; Ware WA; Moran LE; Fales-Williams AJ; Wengert JA; Whitley RD; Betts DM; Boal AM; Riedesel EA; Gross W; Ellinwood NM; Dickson PI
    Sci Transl Med; 2010 Dec; 2(60):60ra89. PubMed ID: 21123810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation.
    Wang D; Shukla C; Liu X; Schoeb TR; Clarke LA; Bedwell DM; Keeling KM
    Mol Genet Metab; 2010 Jan; 99(1):62-71. PubMed ID: 19751987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impaired bone remodeling and its correction by combination therapy in a mouse model of mucopolysaccharidosis-I.
    Kuehn SC; Koehne T; Cornils K; Markmann S; Riedel C; Pestka JM; Schweizer M; Baldauf C; Yorgan TA; Krause M; Keller J; Neven M; Breyer S; Stuecker R; Muschol N; Busse B; Braulke T; Fehse B; Amling M; Schinke T
    Hum Mol Genet; 2015 Dec; 24(24):7075-86. PubMed ID: 26427607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.
    Yogalingam G; Guo XH; Muller VJ; Brooks DA; Clements PR; Kakkis ED; Hopwood JJ
    Hum Mutat; 2004 Sep; 24(3):199-207. PubMed ID: 15300847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mucopolysaccharidoses type I gene therapy.
    Hurt SC; Dickson PI; Curiel DT
    J Inherit Metab Dis; 2021 Sep; 44(5):1088-1098. PubMed ID: 34189746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro gene therapy of mucopolysaccharidosis type I by lentiviral vectors.
    Di Natale P; Di Domenico C; Villani GR; Lombardo A; Follenzi A; Naldini L
    Eur J Biochem; 2002 Jun; 269(11):2764-71. PubMed ID: 12047386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sexual behaviour in a murine model of mucopolysaccharidosis type I (MPS I).
    Barbosa Mendes A; do Nascimento CC; D'Almeida V
    PLoS One; 2019; 14(12):e0220429. PubMed ID: 31834922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose enzyme replacement therapy in murine Hurler syndrome.
    Ou L; Herzog T; Koniar BL; Gunther R; Whitley CB
    Mol Genet Metab; 2014 Feb; 111(2):116-22. PubMed ID: 24100243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type I.
    Osborn MJ; McElmurry RT; Lees CJ; DeFeo AP; Chen ZY; Kay MA; Naldini L; Freeman G; Tolar J; Blazar BR
    Mol Ther; 2011 Mar; 19(3):450-60. PubMed ID: 21081900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice.
    Baldo G; Mayer FQ; Martinelli BZ; de Carvalho TG; Meyer FS; de Oliveira PG; Meurer L; Tavares A; Matte U; Giugliani R
    Mol Genet Metab; 2013 May; 109(1):33-40. PubMed ID: 23562162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type I.
    Ou L; Przybilla MJ; Ahlat O; Kim S; Overn P; Jarnes J; O'Sullivan MG; Whitley CB
    Mol Ther; 2020 Jun; 28(6):1442-1454. PubMed ID: 32278382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retroviral-vector-mediated gene therapy to mucopolysaccharidosis I mice improves sensorimotor impairments and other behavioral deficits.
    Baldo G; Wozniak DF; Ohlemiller KK; Zhang Y; Giugliani R; Ponder KP
    J Inherit Metab Dis; 2013 May; 36(3):499-512. PubMed ID: 22983812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence that glycosaminoglycan storage and collagen deposition in the cauda epididymidis does not impair sperm viability in the Mucopolysaccharidosis type I mouse model.
    do Nascimento CC; Aguiar O; Viana GM; D Almeida V
    Reprod Fertil Dev; 2020 Feb; 32(3):304-312. PubMed ID: 31679559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term nonsense suppression therapy moderates MPS I-H disease progression.
    Gunn G; Dai Y; Du M; Belakhov V; Kandasamy J; Schoeb TR; Baasov T; Bedwell DM; Keeling KM
    Mol Genet Metab; 2014 Mar; 111(3):374-381. PubMed ID: 24411223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In utero injection of alpha-L-iduronidase-carrying retrovirus in canine mucopolysaccharidosis type I: infection of multiple tissues and neonatal gene expression.
    Meertens L; Zhao Y; Rosic-Kablar S; Li L; Chan K; Dobson H; Gartley C; Lutzko C; Hopwood J; Kohn D; Kruth S; Hough MR; Dubé ID
    Hum Gene Ther; 2002 Oct; 13(15):1809-20. PubMed ID: 12396614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosing lysosomal storage disorders: mucopolysaccharidosis type I.
    Johnson BA; Dajnoki A; Bodamer OA
    Curr Protoc Hum Genet; 2015 Jan; 84():17.17.1-17.17.8. PubMed ID: 25599668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene.
    Clarke LA; Russell CS; Pownall S; Warrington CL; Borowski A; Dimmick JE; Toone J; Jirik FR
    Hum Mol Genet; 1997 Apr; 6(4):503-11. PubMed ID: 9097952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.